Burford Capital Limited Operating Income 2011-2026 | BUR

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Burford Capital Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	242 M	234 M	344 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
344 M	234 M	273 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Agenus AGEN	-160 M	$ 3.27	-1.8 %	$ 1.17 M	USA
Agios Pharmaceuticals AGIO	-472 M	$ 29.33	-2.98 %	$ 1.7 B	USA
Akebia Therapeutics AKBA	23.5 M	$ 1.26	-3.44 %	$ 324 M	USA
Akari Therapeutics, Plc AKTX	-21.6 M	$ 0.24	1.1 %	$ 5.73 B	Britain
Aldeyra Therapeutics ALDX	-35.3 M	$ 5.49	0.52 %	$ 330 M	USA
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Alector ALEC	-156 M	$ 2.26	-7.2 %	$ 233 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Aligos Therapeutics ALGS	-88.1 M	$ 7.02	-0.21 %	$ 451 M	USA
Alkermes plc ALKS	254 M	$ 29.32	-2.61 %	$ 4.83 B	Irlanda
Allogene Therapeutics ALLO	-328 M	$ 2.57	-7.73 %	$ 403 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Alnylam Pharmaceuticals ALNY	502 M	$ 330.95	-0.59 %	$ 43.4 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Altimmune ALT	-103 M	$ 4.2	-2.55 %	$ 298 M	USA
ALX Oncology Holdings ALXO	-142 M	$ 2.11	0.09 %	$ 110 M	USA
Amgen AMGN	9.08 B	$ 387.85	0.03 %	$ 209 B	USA
Amphastar Pharmaceuticals AMPH	140 M	$ 20.22	-0.05 %	$ 945 M	USA
Amarin Corporation plc AMRN	-67.6 M	$ 13.62	-1.3 %	$ 5.55 B	Irlanda
AIM ImmunoTech AIM	-19.9 M	$ 0.92	5.25 %	$ 44.2 M	USA
AnaptysBio ANAB	-115 M	$ 54.61	-0.8 %	$ 1.55 B	USA
Anika Therapeutics ANIK	-87.6 M	$ 14.44	0.53 %	$ 212 M	USA
ANI Pharmaceuticals ANIP	584 K	$ 75.31	1.91 %	$ 1.45 B	USA
Annexon ANNX	-154 M	$ 5.38	-3.93 %	$ 739 M	USA
Annovis Bio ANVS	-45 M	$ 2.6	-2.99 %	$ 23.5 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Apellis Pharmaceuticals APLS	55.4 M	$ 20.53	-2.05 %	$ 2.59 B	USA
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Aprea Therapeutics APRE	-15.5 M	$ 0.88	-3.71 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	-24.6 M	$ 7.28	-0.55 %	$ 2.01 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	-47.6 M	-	3.16 %	$ 1.9 M	USA
Aquestive Therapeutics AQST	-30.8 M	$ 3.99	-0.15 %	$ 346 M	USA
Arcturus Therapeutics Holdings ARCT	-95.7 M	$ 8.11	-1.44 %	$ 219 M	Israel
Ardelyx ARDX	-41 M	$ 6.32	-3.54 %	$ 1.52 B	USA
Aileron Therapeutics ALRN	-65.1 M	-	10.36 %	$ 9.8 M	USA
argenx SE ARGX	-349 M	$ 762.51	-0.58 %	$ 25 B	Niderland